Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · IEX Real-Time Price · USD
28.30
+0.66 (2.39%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 525 employees as of September 30, 2023. The number of employees increased by 128 or 32.24% compared to the previous year.
Employees
525
Change (1Y)
128
Growth (1Y)
32.24%
Revenue / Employee
$67,568
Profits / Employee
-$896,741
Market Cap
3.51B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 525 | 128 | 32.24% |
Sep 30, 2022 | 397 | 68 | 20.67% |
Sep 30, 2021 | 329 | 97 | 41.81% |
Sep 30, 2020 | 232 | 98 | 73.13% |
Sep 30, 2019 | 134 | 18 | 15.52% |
Sep 30, 2018 | 116 | 23 | 24.73% |
Sep 30, 2017 | 93 | -20 | -17.70% |
Sep 30, 2016 | 113 | 9 | 8.65% |
Sep 30, 2015 | 104 | 23 | 28.40% |
Sep 30, 2014 | 81 | 27 | 50.00% |
Sep 30, 2013 | 54 | 2 | 3.85% |
Sep 30, 2012 | 52 | 34 | 188.89% |
Sep 30, 2011 | 18 | 0 | - |
Sep 30, 2010 | 18 | -2 | -10.00% |
Sep 30, 2009 | 20 | -48 | -70.59% |
Sep 30, 2008 | 68 | 10 | 17.24% |
Sep 30, 2007 | 58 | 22 | 61.11% |
Sep 30, 2006 | 36 | -11 | -23.40% |
Sep 30, 2005 | 47 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Neogen | 2,640 |
HUTCHMED (China) | 1,988 |
Alvotech | 1,026 |
Axonics | 797 |
PROCEPT BioRobotics | 626 |
Prestige Consumer Healthcare | 560 |
Corcept Therapeutics | 352 |
Merus | 229 |
ARWR News
- 26 days ago - Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course - Business Wire
- 26 days ago - Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE - Business Wire
- 4 weeks ago - 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More - Benzinga
- 7 weeks ago - Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia - Business Wire